Vivos Therapeutics, Inc. Common Stock (VVOS) is a publicly traded Healthcare sector company. As of May 21, 2026, VVOS trades at $0.58 with a market cap of $8.21M and a P/E ratio of -0.29. VVOS moved -0.85% today. Year to date, VVOS is -76.11%; over the trailing twelve months it is -72.49%. Its 52-week range spans $0.57 to $7.95. Analyst consensus is buy with an average price target of $2.42. Rallies surfaces VVOS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Vivos Therapeutics Q1 Revenue Up 70%, Gross Margin Rises to 60%: Vivos Therapeutics Q1 revenue rose 70% to $5.1M, driven by $2.0M in sleep testing services and $0.9M from two acquired SCN locations, lifting gross profit 103% to $3.1M and gross margin to 60%. Net loss doubled to $7.8M as operating expenses climbed 78% to $9.7M, with cash at $2.1M and equity at a $1.1M deficit.
| Metric | Value |
|---|---|
| Price | $0.58 |
| Market Cap | $8.21M |
| P/E Ratio | -0.29 |
| EPS | $-2.07 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.95 |
| 52-Week Low | $0.57 |
| Volume | 50.59K |
| Avg Volume | 0 |
| Revenue (TTM) | $17.44M |
| Net Income | $-21.23M |
| Gross Margin | 60.44% |
3 analysts cover VVOS: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $2.42.